The global inhaled therapy in respiratory disease market size was valued at USD 11.58 billion in 2024 and is predicted to hit around USD 16.22 billion by 2034, rising at a 3.44% CAGR, a study ...
News-Medical.Net on MSN
Cystic fibrosis patients on triple-drug therapy can safely reduce daily lung treatments
A new multi-site study led by researchers at CU Anschutz shows that people with cystic fibrosis (CF) who start the ...
Allied Market Research published a report, titled, "Dyspnea treatment Market - Global Opportunity Analysis and Industry Forecast, 2025-2034", valued at $6,226.61 million in 2024, is poised for ...
Discover how cell-based therapy is emerging as a promising treatment option for COPD patients. Learn about its benefits, ...
The 2025 International Respiratory Immunology Summit, held on Nov 15, brought together leading experts to explore the latest academic advances in respiratory immunology and address critical challenges ...
DelveInsight delivered comprehensive conference coverage across major respiratory events to support a client developing an ...
Many people continue to treat the flu the same way they treat a common cold, and make mistakes that can lead to complications ...
ResMed’s market performance aligns with the S&P 500 index Expanding global reach through advanced healthcare solutions ...
Visakhapatnam: Scrub typhus typically manifests as an acute undifferentiated febrile illness (a sudden-onset fever of varying severity without a clear.
The company has launched Nebzmart® GFB Smartules® and Glenmark Airz® FB Smartules®, world's first nebulised, fixed-dose ...
Glenmark Pharma launches Nebzmart GFB & Airz FB Smartules, a fixed-dose triple therapy for COPD. Improves lung function & ...
Cipla's wants to create awareness, help diagnostics, provide solutions and rehab support, COO Achin Gupta tells Moneycontrol, as the firm doubls down on its lung-care strategy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback